Search results
2 sie 2021 · In patients with VTE (DVT of the leg or PE) we recommend apixaban, dabigatran, edoxaban, or rivaroxaban over vitamin K antagonist (VKA) as treatment-phase (first 3 months) anticoagulant therapy (strong recommendation, moderate-certainty evidence).
- PPT
Forest plot of pooled estimates: any thrombolysis clot...
- Pulmonary Arterial Hypertension and Intraductal Papillary Mucinous Neoplasms of The Pancreas
Pulmonary arterial hypertension (PAH) is a rare,...
- Perioperative Management of Antithrombotic Therapy
The American College of Chest Physicians Clinical Practice...
- Antithrombotic Therapy for VTE Disease
For subsegmental pulmonary embolism and no proximal DVT, we...
- PPT
For subsegmental pulmonary embolism and no proximal DVT, we suggest clinical surveillance over anticoagulation with a low risk of recurrent VTE (Grade 2C), and anticoagulation over clinical surveillance with a high risk (Grade 2C).
5 mar 2024 · In patients with VTE diagnosed in the absence of transient provocation (unprovoked VTE) or VTE provoked by persistent risk factor, we recommend offering extended-phase anticoagulation with a DOAC (Strong Recommendation, Moderate-Certainty Evidence). b
3 sie 2021 · GLENVIEW, Illinois – The American College of Chest Physicians (CHEST) recently released new clinical guidelines for venous thromboembolism (VTE) management, “Antithrombotic Therapy for VTE Disease: Second Update of the CHEST Guideline and Expert Panel” that provides 29 recommendations on 17 Patients, Interventions, Comparators, Outcomes ...
Conditional recommendations include a preference for home treatment for uncomplicated DVT and PE in patients at low risk of complications and a preference for direct-acting oral anticoagulants over vitamin K antagonists for primary treatment of VTE.
2 mar 2016 · For patients with acute DVT, the guideline recommends against the use of compression stockings routinely to prevent the post-thrombotic syndrome (Grade 2B). For patient with subsegmental PE and no DVT, the guideline suggests clinical surveillance over anticoagulation when the risk of VTE recurrence is low (Grade 2C).
Results: The panel generated 29 guidance statements, 13 of which are graded as strong recommendations, covering aspects of antithrombotic management of VTE from initial management through secondary prevention and risk reduction of postthrombotic syndrome. Four new guidance statements have been added that did not appear in the 9th edition (2012 ...
